JP2007502808A - 哺乳類における依存症の予防と治療のための薬剤組成物 - Google Patents
哺乳類における依存症の予防と治療のための薬剤組成物 Download PDFInfo
- Publication number
- JP2007502808A JP2007502808A JP2006523697A JP2006523697A JP2007502808A JP 2007502808 A JP2007502808 A JP 2007502808A JP 2006523697 A JP2006523697 A JP 2006523697A JP 2006523697 A JP2006523697 A JP 2006523697A JP 2007502808 A JP2007502808 A JP 2007502808A
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- phenyl
- aza
- hydroxy
- bicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012335 Dependence Diseases 0.000 title claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 241000124008 Mammalia Species 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title description 9
- 230000002265 prevention Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 claims abstract description 27
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims abstract description 27
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims abstract description 23
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 22
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 21
- 239000003401 opiate antagonist Substances 0.000 claims abstract description 21
- 206010013654 Drug abuse Diseases 0.000 claims abstract description 15
- 208000022497 Cocaine-Related disease Diseases 0.000 claims abstract description 12
- 230000003542 behavioural effect Effects 0.000 claims abstract description 12
- 206010013663 drug dependence Diseases 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- 208000029650 alcohol withdrawal Diseases 0.000 claims abstract description 11
- 201000006145 cocaine dependence Diseases 0.000 claims abstract description 11
- 208000001613 Gambling Diseases 0.000 claims abstract description 9
- 208000024891 symptom Diseases 0.000 claims abstract description 8
- 241000208125 Nicotiana Species 0.000 claims abstract description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- -1 1-methyl-1-phenyl-ethyl Chemical group 0.000 claims description 74
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 38
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 37
- KBPHGUKTJKPERJ-UHFFFAOYSA-N 2-methoxyethanesulfonic acid Chemical compound COCCS(O)(=O)=O KBPHGUKTJKPERJ-UHFFFAOYSA-N 0.000 claims description 32
- 150000001408 amides Chemical class 0.000 claims description 32
- 150000004677 hydrates Chemical class 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 9
- NOVIRJZSSSHOFF-UHFFFAOYSA-N 3-[1-(2,3-dihydro-1h-inden-2-ylmethyl)-3,4-dimethylpiperidin-4-yl]benzamide Chemical compound CC1CN(CC2CC3=CC=CC=C3C2)CCC1(C)C1=CC=CC(C(N)=O)=C1 NOVIRJZSSSHOFF-UHFFFAOYSA-N 0.000 claims description 8
- CMXNJCYHOYIGPE-UHFFFAOYSA-N 3-[1-[(1-hydroxy-3-phenylcyclobutyl)methyl]-3,4-dimethylpiperidin-4-yl]benzamide Chemical compound C1CC(C=2C=C(C=CC=2)C(N)=O)(C)C(C)CN1CC(C1)(O)CC1C1=CC=CC=C1 CMXNJCYHOYIGPE-UHFFFAOYSA-N 0.000 claims description 8
- VLJHXPKDNBNFPN-UHFFFAOYSA-N 3-[1-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-3,4-dimethylpiperidin-4-yl]benzamide Chemical compound CC1CN(CC2(O)CC3=CC=CC=C3C2)CCC1(C)C1=CC=CC(C(N)=O)=C1 VLJHXPKDNBNFPN-UHFFFAOYSA-N 0.000 claims description 8
- LTENPJFSBSGWFV-UHFFFAOYSA-N 3-[1-[3-(1-hydroxycyclohexyl)propyl]-3,4-dimethylpiperidin-4-yl]benzamide Chemical compound C1CC(C=2C=C(C=CC=2)C(N)=O)(C)C(C)CN1CCCC1(O)CCCCC1 LTENPJFSBSGWFV-UHFFFAOYSA-N 0.000 claims description 8
- YZMRJTFTIRSULG-UHFFFAOYSA-N 3-[2-[(1-hydroxy-3-phenylcyclobutyl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C23CC(CCC2)N(CC2(O)CC(C2)C=2C=CC=CC=2)CC3)=C1 YZMRJTFTIRSULG-UHFFFAOYSA-N 0.000 claims description 8
- ZCDWSEYWBPLIPE-UHFFFAOYSA-N 3-[2-[(2-hydroxy-3,4-dihydro-1h-naphthalen-2-yl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C23CC(CCC2)N(CC2(O)CC4=CC=CC=C4CC2)CC3)=C1 ZCDWSEYWBPLIPE-UHFFFAOYSA-N 0.000 claims description 8
- KDAMUYVTYZYYMY-UHFFFAOYSA-N 3-[2-[3-(1-hydroxycyclohexyl)propyl]-2-azabicyclo[3.3.1]nonan-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C23CC(CCC2)N(CCCC2(O)CCCCC2)CC3)=C1 KDAMUYVTYZYYMY-UHFFFAOYSA-N 0.000 claims description 8
- NQDNSVFGDWTZRD-UHFFFAOYSA-N 3-[3-(2,3-dihydro-1h-inden-2-ylmethyl)-6-ethyl-3-azabicyclo[3.1.0]hexan-6-yl]benzamide Chemical compound C12CN(CC3CC4=CC=CC=C4C3)CC2C1(CC)C1=CC=CC(C(N)=O)=C1 NQDNSVFGDWTZRD-UHFFFAOYSA-N 0.000 claims description 8
- PNUIAAYEYHRGJI-UHFFFAOYSA-N 3-[3-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]octan-8-yl]benzamide Chemical compound C1N(CC2(O)CC3=CC=CC=C3C2)CC2CCC1C2(OC)C1=CC=CC(C(N)=O)=C1 PNUIAAYEYHRGJI-UHFFFAOYSA-N 0.000 claims description 8
- PCUUSYJXGVLVTO-UHFFFAOYSA-N 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]octan-8-yl]benzamide Chemical compound C=1C=CC(C(N)=O)=CC=1C1(OC)C(C2)CCC1CN2CCCC1(O)CCCCC1 PCUUSYJXGVLVTO-UHFFFAOYSA-N 0.000 claims description 8
- KJJLEOOLZLWLSS-UHFFFAOYSA-N 3-[6-ethyl-3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]benzamide Chemical compound C1C2C(CC)(C=3C=C(C=CC=3)C(N)=O)C2CN1CC(C1)(O)CC1C1=CC=CC=C1 KJJLEOOLZLWLSS-UHFFFAOYSA-N 0.000 claims description 8
- SCNSHBHEDUUZDM-UHFFFAOYSA-N 3-[6-ethyl-3-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]benzamide Chemical compound C12CN(CC3(O)CC4=CC=CC=C4C3)CC2C1(CC)C1=CC=CC(C(N)=O)=C1 SCNSHBHEDUUZDM-UHFFFAOYSA-N 0.000 claims description 8
- ZFMTXYPTAWEVCX-UHFFFAOYSA-N 3-[6-ethyl-3-[(2-hydroxy-3,4-dihydro-1h-naphthalen-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]benzamide Chemical compound C12CN(CC3(O)CC4=CC=CC=C4CC3)CC2C1(CC)C1=CC=CC(C(N)=O)=C1 ZFMTXYPTAWEVCX-UHFFFAOYSA-N 0.000 claims description 8
- IIMDLDQJDZKMRU-UHFFFAOYSA-N 3-[6-ethyl-3-[3-(1-hydroxycyclohexyl)propyl]-3-azabicyclo[3.1.0]hexan-6-yl]benzamide Chemical compound C1C2C(CC)(C=3C=C(C=CC=3)C(N)=O)C2CN1CCCC1(O)CCCCC1 IIMDLDQJDZKMRU-UHFFFAOYSA-N 0.000 claims description 8
- DQASZCKCSVFDCH-UHFFFAOYSA-N n-[3-[2-[(1-hydroxy-3-phenylcyclobutyl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]phenyl]-2-methoxyethanesulfonamide Chemical compound COCCS(=O)(=O)NC1=CC=CC(C23CC(CCC2)N(CC2(O)CC(C2)C=2C=CC=CC=2)CC3)=C1 DQASZCKCSVFDCH-UHFFFAOYSA-N 0.000 claims description 8
- RQZJNXFHIROAPH-UHFFFAOYSA-N n-[3-[2-[(1-hydroxy-3-phenylcyclobutyl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C23CC(CCC2)N(CC2(O)CC(C2)C=2C=CC=CC=2)CC3)=C1 RQZJNXFHIROAPH-UHFFFAOYSA-N 0.000 claims description 8
- PARWEPAVIFDMQQ-UHFFFAOYSA-N n-[3-[2-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]phenyl]-2-methoxyethanesulfonamide Chemical compound COCCS(=O)(=O)NC1=CC=CC(C23CC(CCC2)N(CC2(O)CC4=CC=CC=C4C2)CC3)=C1 PARWEPAVIFDMQQ-UHFFFAOYSA-N 0.000 claims description 8
- MWQBBRUNZRMVLU-UHFFFAOYSA-N n-[3-[2-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C23CC(CCC2)N(CC2(O)CC4=CC=CC=C4C2)CC3)=C1 MWQBBRUNZRMVLU-UHFFFAOYSA-N 0.000 claims description 8
- HFTKEKZOAHFQKB-UHFFFAOYSA-N n-[3-[2-[(2-hydroxy-3,4-dihydro-1h-naphthalen-2-yl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C23CC(CCC2)N(CC2(O)CC4=CC=CC=C4CC2)CC3)=C1 HFTKEKZOAHFQKB-UHFFFAOYSA-N 0.000 claims description 8
- VWHWAPBGKJVPNM-UHFFFAOYSA-N n-[3-[2-[3-(1-hydroxycyclohexyl)propyl]-2-azabicyclo[3.3.1]nonan-5-yl]phenyl]-2-methoxyethanesulfonamide Chemical compound COCCS(=O)(=O)NC1=CC=CC(C23CC(CCC2)N(CCCC2(O)CCCCC2)CC3)=C1 VWHWAPBGKJVPNM-UHFFFAOYSA-N 0.000 claims description 8
- VWCPRVNVISOSDS-UHFFFAOYSA-N n-[3-[2-[3-(1-hydroxycyclohexyl)propyl]-2-azabicyclo[3.3.1]nonan-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C23CC(CCC2)N(CCCC2(O)CCCCC2)CC3)=C1 VWCPRVNVISOSDS-UHFFFAOYSA-N 0.000 claims description 8
- UWTVBOIAYXZBRE-UHFFFAOYSA-N n-[3-[3-(2,3-dihydro-1h-inden-2-ylmethyl)-6-ethyl-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-2-methoxyethanesulfonamide Chemical compound C12CN(CC3CC4=CC=CC=C4C3)CC2C1(CC)C1=CC=CC(NS(=O)(=O)CCOC)=C1 UWTVBOIAYXZBRE-UHFFFAOYSA-N 0.000 claims description 8
- GDHQBJVFNKIBKI-UHFFFAOYSA-N n-[3-[3-(2,3-dihydro-1h-inden-2-ylmethyl)-6-ethyl-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]methanesulfonamide Chemical compound C12CN(CC3CC4=CC=CC=C4C3)CC2C1(CC)C1=CC=CC(NS(C)(=O)=O)=C1 GDHQBJVFNKIBKI-UHFFFAOYSA-N 0.000 claims description 8
- YXMNCEWFXWZDRL-UHFFFAOYSA-N n-[3-[3-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]octan-8-yl]phenyl]methanesulfonamide Chemical compound C1N(CC2(O)CC3=CC=CC=C3C2)CC2CCC1C2(OC)C1=CC=CC(NS(C)(=O)=O)=C1 YXMNCEWFXWZDRL-UHFFFAOYSA-N 0.000 claims description 8
- ZBVPUFSKFGYNLC-UHFFFAOYSA-N n-[3-[6-ethyl-3-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]methanesulfonamide Chemical compound C12CN(CC3(O)CC4=CC=CC=C4C3)CC2C1(CC)C1=CC=CC(NS(C)(=O)=O)=C1 ZBVPUFSKFGYNLC-UHFFFAOYSA-N 0.000 claims description 8
- LWWRWOHYBARKAQ-UHFFFAOYSA-N n-[3-[6-ethyl-3-[3-(1-hydroxycyclohexyl)propyl]-3-azabicyclo[3.1.0]hexan-6-yl]phenyl]-2-methoxyethanesulfonamide Chemical compound C1C2C(CC)(C=3C=C(NS(=O)(=O)CCOC)C=CC=3)C2CN1CCCC1(O)CCCCC1 LWWRWOHYBARKAQ-UHFFFAOYSA-N 0.000 claims description 8
- XWJBBHRGYQANKK-UHFFFAOYSA-N 3-[2-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-2-azabicyclo[3.3.1]nonan-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C23CC(CCC2)N(CC2(O)CC4=CC=CC=C4C2)CC3)=C1 XWJBBHRGYQANKK-UHFFFAOYSA-N 0.000 claims description 7
- CQMGDWUBLFGSDQ-UHFFFAOYSA-N 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]octan-8-yl]benzamide Chemical compound C=1C=CC(C(N)=O)=CC=1C1(OC)C(C2)CCC1CN2CC(C1)(O)CC1C1=CC=CC=C1 CQMGDWUBLFGSDQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960003920 cocaine Drugs 0.000 claims description 7
- YBQGLTGAHBCMME-UHFFFAOYSA-N 4-amino-1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)(N)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 YBQGLTGAHBCMME-UHFFFAOYSA-N 0.000 claims description 5
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 5
- UNAZAADNBYXMIV-UHFFFAOYSA-N otenabant Chemical compound C1CC(NCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 UNAZAADNBYXMIV-UHFFFAOYSA-N 0.000 claims description 5
- CZLBJIOKKYHVOG-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-3-(ethylamino)azetidine-3-carboxamide Chemical compound C1C(NCC)(C(N)=O)CN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 CZLBJIOKKYHVOG-UHFFFAOYSA-N 0.000 claims description 4
- ZNNPDKATJWCFJB-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-4-(ethylamino)piperidine-4-carboxamide Chemical compound C1CC(NCC)(C(N)=O)CCN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 ZNNPDKATJWCFJB-UHFFFAOYSA-N 0.000 claims description 4
- XJFUIILGVMOOHV-UHFFFAOYSA-N 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-(ethylamino)azetidine-3-carboxamide Chemical compound C1C(NCC)(C(N)=O)CN1C1=NC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 XJFUIILGVMOOHV-UHFFFAOYSA-N 0.000 claims description 4
- HYBPYDGGQPVUBJ-UHFFFAOYSA-N 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-(propan-2-ylamino)azetidine-3-carboxamide Chemical compound C1C(NC(C)C)(C(N)=O)CN1C1=NC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 HYBPYDGGQPVUBJ-UHFFFAOYSA-N 0.000 claims description 4
- SQSZXZKMVHUPRD-UHFFFAOYSA-N 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(propan-2-ylamino)piperidine-4-carboxamide Chemical compound C1CC(NC(C)C)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 SQSZXZKMVHUPRD-UHFFFAOYSA-N 0.000 claims description 4
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 4
- FMQLEHWCAMNBAG-UHFFFAOYSA-N 8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-1-propan-2-yl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound CC(C)N1CNC(=O)C11CCN(C=2N3N=C(C(=C3N=C(C)N=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)CC1 FMQLEHWCAMNBAG-UHFFFAOYSA-N 0.000 claims description 4
- 206010057852 Nicotine dependence Diseases 0.000 claims description 4
- INMZIBQWBSNYED-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-4-(propan-2-ylamino)piperidine-4-carboxamide Chemical compound C1CC(NC(C)C)(C(N)=O)CCN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 INMZIBQWBSNYED-UHFFFAOYSA-N 0.000 claims description 3
- DDLXFJXATMJVFP-UHFFFAOYSA-N 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-3-(ethylamino)azetidine-3-carboxamide Chemical compound C1C(NCC)(C(N)=O)CN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 DDLXFJXATMJVFP-UHFFFAOYSA-N 0.000 claims description 3
- CGAZBXQGGFUKJS-UHFFFAOYSA-N 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)purin-6-yl]-4-(propan-2-ylamino)piperidine-4-carboxamide Chemical compound C1CC(NC(C)C)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)F)N2C1=CC=C(Cl)C=C1 CGAZBXQGGFUKJS-UHFFFAOYSA-N 0.000 claims description 3
- QVYSNUZRPPOOSX-UHFFFAOYSA-N 8-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1-propan-2-yl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound CC(C)N1CNC(=O)C11CCN(C=2N3N=C(C(=C3N=CC=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)CC1 QVYSNUZRPPOOSX-UHFFFAOYSA-N 0.000 claims description 3
- MGXWXNOHTWTTFC-UHFFFAOYSA-N 8-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-1-propan-2-yl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound CC(C)N1CNC(=O)C11CCN(C=2C=3N=C(N(C=3N=CN=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)CC1 MGXWXNOHTWTTFC-UHFFFAOYSA-N 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- NBBLBZXXTIHYGR-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-[1-(2,2-dimethyloxan-4-yl)imidazol-4-yl]-4-methylpyrazole Chemical compound CC=1C(C=2N=CN(C=2)C2CC(C)(C)OCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 NBBLBZXXTIHYGR-UHFFFAOYSA-N 0.000 claims description 2
- RSHRLSNTSNPHBI-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-3-[1-(1-phenylethyl)imidazol-4-yl]pyrazole Chemical compound C1=NC(C=2C(=C(N(N=2)C=2C(=CC=CC=2)Cl)C=2C=CC(Cl)=CC=2)C)=CN1C(C)C1=CC=CC=C1 RSHRLSNTSNPHBI-UHFFFAOYSA-N 0.000 claims description 2
- CTSFSQZYEGEKNJ-UHFFFAOYSA-N 1-(oxazepan-4-yl)ethanone Chemical compound O1NCC(CCC1)C(C)=O CTSFSQZYEGEKNJ-UHFFFAOYSA-N 0.000 claims description 2
- KIJMGJWYLBFNAV-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-(1-oxa-8-azaspiro[4.5]decan-8-yl)ethanone Chemical compound CC=1C(C(=O)CN2CCC3(OCCC3)CC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 KIJMGJWYLBFNAV-UHFFFAOYSA-N 0.000 claims description 2
- KGJHVABFBBJFIG-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-(3,3-dimethylpiperidin-1-yl)ethanol Chemical compound CC=1C(C(O)CN2CC(C)(C)CCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 KGJHVABFBBJFIG-UHFFFAOYSA-N 0.000 claims description 2
- FLLKDUQZOAVVFU-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-(3,5-dimethylpiperidin-1-yl)ethanol Chemical compound C1C(C)CC(C)CN1CC(O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1C FLLKDUQZOAVVFU-UHFFFAOYSA-N 0.000 claims description 2
- CSIFSTSKGZGCOA-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-[4-(1-methylcyclopropanecarbonyl)piperazin-1-yl]ethanone Chemical compound CC=1C(C(=O)CN2CCN(CC2)C(=O)C2(C)CC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CSIFSTSKGZGCOA-UHFFFAOYSA-N 0.000 claims description 2
- ZIKXMOOJNIZFNL-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-morpholin-4-ylethanol Chemical compound CC=1C(C(O)CN2CCOCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 ZIKXMOOJNIZFNL-UHFFFAOYSA-N 0.000 claims description 2
- JBCFDMJWDPFMLH-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-morpholin-4-ylethanone Chemical compound CC=1C(C(=O)CN2CCOCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JBCFDMJWDPFMLH-UHFFFAOYSA-N 0.000 claims description 2
- WFUGOPUQRHLVDJ-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-piperidin-1-ylethanol Chemical compound CC=1C(C(O)CN2CCCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 WFUGOPUQRHLVDJ-UHFFFAOYSA-N 0.000 claims description 2
- KEKFWCUOYHQBHF-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-piperidin-1-ylethanone Chemical compound CC=1C(C(=O)CN2CCCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 KEKFWCUOYHQBHF-UHFFFAOYSA-N 0.000 claims description 2
- LMVIYCSQQODEFW-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-pyrrolidin-1-ylethanone Chemical compound CC=1C(C(=O)CN2CCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 LMVIYCSQQODEFW-UHFFFAOYSA-N 0.000 claims description 2
- HUKVRWGDXWJBMB-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazol-4-yl]-2-piperidin-1-ylethanone Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)CN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl HUKVRWGDXWJBMB-UHFFFAOYSA-N 0.000 claims description 2
- MWSIWMOUSACWNX-UHFFFAOYSA-N 1-[1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-4-phenylpiperidin-4-yl]ethanone Chemical compound C1CC(C(=O)C)(C=2C=CC=CC=2)CCN1C(N1N=2)=CC=NC1=C(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl MWSIWMOUSACWNX-UHFFFAOYSA-N 0.000 claims description 2
- WQVGMYAFQBQBBH-UHFFFAOYSA-N 1-[1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-phenylpiperidin-4-yl]ethanone Chemical compound C1CC(C(=O)C)(C=2C=CC=CC=2)CCN1C(N1N=2)=NC(C)=NC1=C(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl WQVGMYAFQBQBBH-UHFFFAOYSA-N 0.000 claims description 2
- FETSMMUOWHGTGJ-UHFFFAOYSA-N 1-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-phenylpiperidin-4-yl]ethanone Chemical compound C1CC(C(=O)C)(C=2C=CC=CC=2)CCN1C(C=1N=2)=NC=NC=1N(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl FETSMMUOWHGTGJ-UHFFFAOYSA-N 0.000 claims description 2
- KVAARXBFBPNASW-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-yl]-3-(ethylamino)azetidine-3-carboxamide Chemical compound C1C(NCC)(C(N)=O)CN1C1=C(C)C=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 KVAARXBFBPNASW-UHFFFAOYSA-N 0.000 claims description 2
- HVXLAPMGPSSUAP-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-3-(methylamino)azetidine-3-carboxamide Chemical compound C1C(NC)(C(N)=O)CN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 HVXLAPMGPSSUAP-UHFFFAOYSA-N 0.000 claims description 2
- IKIJBYVYJILIOG-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-3-(propan-2-ylamino)azetidine-3-carboxamide Chemical compound C1C(NC(C)C)(C(N)=O)CN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 IKIJBYVYJILIOG-UHFFFAOYSA-N 0.000 claims description 2
- LRZAPFUQVRSILO-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-4-(4-fluorophenyl)piperidin-4-ol Chemical compound C1CC(O)(C=2C=CC(F)=CC=2)CCN1C(N1N=2)=CC=NC1=C(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl LRZAPFUQVRSILO-UHFFFAOYSA-N 0.000 claims description 2
- QIDQDWXTIVTKSA-UHFFFAOYSA-N 1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-hydroxyethyl]-4-(propan-2-ylamino)piperidine-4-carboxamide Chemical compound C1CC(NC(C)C)(C(N)=O)CCN1CC(O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1C QIDQDWXTIVTKSA-UHFFFAOYSA-N 0.000 claims description 2
- IEYCJVQOXJOJMF-UHFFFAOYSA-N 1-[4-[2-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methylpyrazol-3-yl]-2-oxoethyl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound CC=1C(C(=O)CN2CCN(CC2)C(=O)C(F)(F)F)=NN(C=2C(=CC=CC=2)F)C=1C1=CC=C(Cl)C=C1 IEYCJVQOXJOJMF-UHFFFAOYSA-N 0.000 claims description 2
- KXERESOFXDHWKC-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methylpyrazol-3-yl]-2-morpholin-4-ylethanone Chemical compound CC=1C(C(=O)CN2CCOCC2)=NN(C=2C(=CC=CC=2)F)C=1C1=CC=C(Cl)C=C1 KXERESOFXDHWKC-UHFFFAOYSA-N 0.000 claims description 2
- GWYHSUUKVUYTOI-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methylpyrazol-3-yl]-2-piperidin-1-ylethanone Chemical compound CC=1C(C(=O)CN2CCCCC2)=NN(C=2C(=CC=CC=2)F)C=1C1=CC=C(Cl)C=C1 GWYHSUUKVUYTOI-UHFFFAOYSA-N 0.000 claims description 2
- CGWCKCIUPFTWIW-UHFFFAOYSA-N 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-(dimethylamino)azetidine-3-carboxamide Chemical compound C1C(N(C)C)(C(N)=O)CN1C1=NC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 CGWCKCIUPFTWIW-UHFFFAOYSA-N 0.000 claims description 2
- QYIBQMXFMBCSBZ-UHFFFAOYSA-N 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-(methylamino)azetidine-3-carboxamide Chemical compound C1C(NC)(C(N)=O)CN1C1=NC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 QYIBQMXFMBCSBZ-UHFFFAOYSA-N 0.000 claims description 2
- QVAHSBWLKXHTQC-UHFFFAOYSA-N 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-(ethylamino)piperidine-4-carboxamide Chemical compound C1CC(NCC)(C(N)=O)CCN1C1=NC(C)=NC2=C(C=3C=CC(F)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 QVAHSBWLKXHTQC-UHFFFAOYSA-N 0.000 claims description 2
- LLAJVGJOIHYXEM-UHFFFAOYSA-N 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-3-(propan-2-ylamino)azetidine-3-carboxamide Chemical compound C1C(NC(C)C)(C(N)=O)CN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 LLAJVGJOIHYXEM-UHFFFAOYSA-N 0.000 claims description 2
- RPDYFJQLDFRNNV-UHFFFAOYSA-N 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(4-fluorophenyl)piperidin-4-ol Chemical compound C1CC(O)(C=2C=CC(F)=CC=2)CCN1C(C=1N=2)=NC=NC=1N(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl RPDYFJQLDFRNNV-UHFFFAOYSA-N 0.000 claims description 2
- RSSDYHXNXTWNJY-UHFFFAOYSA-N 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(propylamino)piperidine-4-carboxamide Chemical compound C1CC(NCCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 RSSDYHXNXTWNJY-UHFFFAOYSA-N 0.000 claims description 2
- SKJBKOGUSSCGFF-UHFFFAOYSA-N 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-phenylpiperidin-4-ol Chemical compound C1CC(O)(C=2C=CC=CC=2)CCN1C(C=1N=2)=NC=NC=1N(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl SKJBKOGUSSCGFF-UHFFFAOYSA-N 0.000 claims description 2
- XGMUXVHFGMMZJM-UHFFFAOYSA-N 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)purin-6-yl]-4-(propylamino)piperidine-4-carboxamide Chemical compound C1CC(NCCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC(Cl)=CC=1)Cl)N2C1=CC=C(Cl)C=C1 XGMUXVHFGMMZJM-UHFFFAOYSA-N 0.000 claims description 2
- LGRHTFQDJMGCCC-UHFFFAOYSA-N 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methylpurin-6-yl]-4-(propan-2-ylamino)piperidine-4-carboxamide Chemical compound C1CC(NC(C)C)(C(N)=O)CCN1C1=NC(C)=NC2=C1N=C(C=1C(=CC=CC=1)F)N2C1=CC=C(Cl)C=C1 LGRHTFQDJMGCCC-UHFFFAOYSA-N 0.000 claims description 2
- WNKABPFCNZDXLQ-UHFFFAOYSA-N 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)purin-6-yl]-4-(propylamino)piperidine-4-carboxamide Chemical compound C1CC(NCCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)F)N2C1=CC=C(Cl)C=C1 WNKABPFCNZDXLQ-UHFFFAOYSA-N 0.000 claims description 2
- FPEJMPNMDFPDIC-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(1-cyclohexylazetidin-3-yl)oxypyrazolo[1,5-a]pyrimidine Chemical compound C1=CC(Cl)=CC=C1C1=C2N=CC=C(OC3CN(C3)C3CCCCC3)N2N=C1C1=CC=CC=C1Cl FPEJMPNMDFPDIC-UHFFFAOYSA-N 0.000 claims description 2
- RZXDBUXHRVUUCT-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 RZXDBUXHRVUUCT-UHFFFAOYSA-N 0.000 claims description 2
- HRVLVKUGKPHPML-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(4-propan-2-ylsulfonylpiperazin-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound C1CN(S(=O)(=O)C(C)C)CCN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 HRVLVKUGKPHPML-UHFFFAOYSA-N 0.000 claims description 2
- RLCOBFXHEJIMNV-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(4-pyrimidin-2-ylpiperazin-1-yl)pyrazolo[1,5-a]pyrimidine Chemical compound C1=CC(Cl)=CC=C1C1=C2N=CC=C(N3CCN(CC3)C=3N=CC=CN=3)N2N=C1C1=CC=CC=C1Cl RLCOBFXHEJIMNV-UHFFFAOYSA-N 0.000 claims description 2
- ZPNFYIDUUCATFJ-ROUUACIJSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[(1s,4s)-2-methylsulfonyl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrazolo[1,5-a]pyrimidine Chemical compound C([C@]1(N(C[C@@]2(C1)[H])S(C)(=O)=O)[H])N2C(N1N=2)=CC=NC1=C(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl ZPNFYIDUUCATFJ-ROUUACIJSA-N 0.000 claims description 2
- VXODHBBNQFCLHC-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-2,5,7-triazaspiro[3.4]octan-8-one Chemical compound C1=CC(Cl)=CC=C1C1=C2N=CC=C(N3CC4(C3)C(NCN4)=O)N2N=C1C1=CC=CC=C1Cl VXODHBBNQFCLHC-UHFFFAOYSA-N 0.000 claims description 2
- QPQIOJLYMHFFPR-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-5-methyl-2,5,7-triazaspiro[3.4]octan-8-one Chemical compound CN1CNC(=O)C11CN(C=2N3N=C(C(=C3N=CC=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)C1 QPQIOJLYMHFFPR-UHFFFAOYSA-N 0.000 claims description 2
- JQUHYJSCKDSSEF-UHFFFAOYSA-N 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5,7-triazaspiro[3.4]octan-8-one Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1N(C1)CC21NCNC2=O JQUHYJSCKDSSEF-UHFFFAOYSA-N 0.000 claims description 2
- PWRILIKTEISCFH-UHFFFAOYSA-N 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-5-methyl-2,5,7-triazaspiro[3.4]octan-8-one Chemical compound CN1CNC(=O)C11CN(C=2N3N=C(C(=C3N=C(C)N=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)C1 PWRILIKTEISCFH-UHFFFAOYSA-N 0.000 claims description 2
- IUPOIIZOBOILLK-UHFFFAOYSA-N 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-6,6-dimethyl-2,5,7-triazaspiro[3.4]octan-8-one Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1N(C1)CC21NC(C)(C)NC2=O IUPOIIZOBOILLK-UHFFFAOYSA-N 0.000 claims description 2
- UJXKCJMVVWMQAC-UHFFFAOYSA-N 2-[benzyl(propan-2-yl)amino]-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]ethanol Chemical compound C=1C=CC=CC=1CN(C(C)C)CC(O)C(C=1C)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 UJXKCJMVVWMQAC-UHFFFAOYSA-N 0.000 claims description 2
- JYGHUGGSDYHOAD-UHFFFAOYSA-N 3-amino-1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]azetidine-3-carboxamide Chemical compound C1C(C(=O)N)(N)CN1C1=CC=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 JYGHUGGSDYHOAD-UHFFFAOYSA-N 0.000 claims description 2
- CEHKZYSVOCFNRQ-UHFFFAOYSA-N 3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]azetidine-3-carboxamide Chemical class N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1N1CC(N)(C(N)=O)C1 CEHKZYSVOCFNRQ-UHFFFAOYSA-N 0.000 claims description 2
- OEOZSLHGXZGCMK-UHFFFAOYSA-N 4-(1-benzylpyrrolidin-3-yl)oxy-7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazine Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1OC(C1)CCN1CC1=CC=CC=C1 OEOZSLHGXZGCMK-UHFFFAOYSA-N 0.000 claims description 2
- KPDICBIFKOBCOP-UHFFFAOYSA-N 4-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]morpholine Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1N1CCOCC1 KPDICBIFKOBCOP-UHFFFAOYSA-N 0.000 claims description 2
- DNPSMAHBGIQJNC-UHFFFAOYSA-N 4-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-n-methylpiperazine-2-carboxamide Chemical compound C1CNC(C(=O)NC)CN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 DNPSMAHBGIQJNC-UHFFFAOYSA-N 0.000 claims description 2
- CQGPFLMUTINLFP-UHFFFAOYSA-N 4-benzyl-1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]piperidin-4-ol Chemical compound C1CN(C=2N3N=C(C(=C3N=CC=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)CCC1(O)CC1=CC=CC=C1 CQGPFLMUTINLFP-UHFFFAOYSA-N 0.000 claims description 2
- HUZIHJMYKVLBGE-UHFFFAOYSA-N 4-benzyl-1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-ol Chemical compound C1CN(C=2C=3N=C(N(C=3N=CN=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)CCC1(O)CC1=CC=CC=C1 HUZIHJMYKVLBGE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- IHUJIWXYFXDLJI-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-[1-(2-phenylpropan-2-yl)imidazol-4-yl]pyrazole Chemical compound CC=1C(C=2N=CN(C=2)C(C)(C)C=2C=CC=CC=2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 IHUJIWXYFXDLJI-UHFFFAOYSA-N 0.000 claims description 2
- DQCGCILDBMFEOE-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methyl-3-[1-(2-phenylpropan-2-yl)imidazol-4-yl]pyrazole Chemical compound CC=1C(C=2N=CN(C=2)C(C)(C)C=2C=CC=CC=2)=NN(C=2C(=CC=CC=2)F)C=1C1=CC=C(Cl)C=C1 DQCGCILDBMFEOE-UHFFFAOYSA-N 0.000 claims description 2
- KPQBABKRCICYCP-UHFFFAOYSA-N 5-(4-chlorophenyl)-3-(2-cyclohexyl-1H-imidazol-5-yl)-1-(2,4-dichlorophenyl)-4-methylpyrazole Chemical compound CC=1C(C=2NC(=NC=2)C2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 KPQBABKRCICYCP-UHFFFAOYSA-N 0.000 claims description 2
- MAOZBIOYMACLOW-UHFFFAOYSA-N 5-(4-chlorophenyl)-3-(5-cyclohexyl-1H-imidazol-2-yl)-1-(2,4-dichlorophenyl)-4-methylpyrazole Chemical compound CC=1C(C=2NC(=CN=2)C2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 MAOZBIOYMACLOW-UHFFFAOYSA-N 0.000 claims description 2
- MBJUYTICAOCFKW-UHFFFAOYSA-N 5-[2-(2,4-dichlorophenyl)-4-methyl-5-[1-(2-phenylpropan-2-yl)imidazol-4-yl]pyrazol-3-yl]-2-methoxypyridine Chemical compound C1=NC(OC)=CC=C1C1=C(C)C(C=2N=CN(C=2)C(C)(C)C=2C=CC=CC=2)=NN1C1=CC=C(Cl)C=C1Cl MBJUYTICAOCFKW-UHFFFAOYSA-N 0.000 claims description 2
- MZRPLPNMEBKVMW-UHFFFAOYSA-N 6-(1-benzylpyrrolidin-3-yl)oxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)purine Chemical compound C1=CC(Cl)=CC=C1N1C2=NC=NC(OC3CN(CC=4C=CC=CC=4)CC3)=C2N=C1C1=CC=C(Cl)C=C1Cl MZRPLPNMEBKVMW-UHFFFAOYSA-N 0.000 claims description 2
- CYZRHEQQZJGZRH-UHFFFAOYSA-N 7-(1-benzylpyrrolidin-3-yl)oxy-2-(2-chlorophenyl)-3-(4-chlorophenyl)pyrazolo[1,5-a]pyrimidine Chemical compound C1=CC(Cl)=CC=C1C1=C2N=CC=C(OC3CN(CC=4C=CC=CC=4)CC3)N2N=C1C1=CC=CC=C1Cl CYZRHEQQZJGZRH-UHFFFAOYSA-N 0.000 claims description 2
- MPCZFCKCHMXKSZ-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-propan-2-ylsulfonylpiperazin-1-yl)pyrazolo[1,5-a][1,3,5]triazine Chemical compound C1CN(S(=O)(=O)C(C)C)CCN1C1=NC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 MPCZFCKCHMXKSZ-UHFFFAOYSA-N 0.000 claims description 2
- VUTLQAOPBPMEKF-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrazolo[1,5-a][1,3,5]triazine Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1N(CC1)CCN1C1=NC=CC=N1 VUTLQAOPBPMEKF-UHFFFAOYSA-N 0.000 claims description 2
- OCQLVFVXVCTHHD-ROUUACIJSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-[(1s,4s)-2-methylsulfonyl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrazolo[1,5-a][1,3,5]triazine Chemical compound C([C@]1(N(C[C@@]2(C1)[H])S(C)(=O)=O)[H])N2C(N1N=2)=NC(C)=NC1=C(C=1C=CC(Cl)=CC=1)C=2C1=CC=CC=C1Cl OCQLVFVXVCTHHD-ROUUACIJSA-N 0.000 claims description 2
- GPSKJJNUXWWNBR-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-piperidin-1-ylpyrazolo[1,5-a][1,3,5]triazine Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1N1CCCCC1 GPSKJJNUXWWNBR-UHFFFAOYSA-N 0.000 claims description 2
- WKMDUNKYIDESRF-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-propan-2-yloxypyrazolo[1,5-a][1,3,5]triazine Chemical compound N=1N2C(OC(C)C)=NC(C)=NC2=C(C=2C=CC(Cl)=CC=2)C=1C1=CC=CC=C1Cl WKMDUNKYIDESRF-UHFFFAOYSA-N 0.000 claims description 2
- BSEUFVUYWQGTQO-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-n-(2-morpholin-4-ylethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1NCCN1CCOCC1 BSEUFVUYWQGTQO-UHFFFAOYSA-N 0.000 claims description 2
- BACFLWLVLGFHMI-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-(1-cyclohexylazetidin-3-yl)oxy-2-methylpyrazolo[1,5-a][1,3,5]triazine Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1OC(C1)CN1C1CCCCC1 BACFLWLVLGFHMI-UHFFFAOYSA-N 0.000 claims description 2
- QDDSPBSONLNBDS-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-n-[2-(4-fluorophenyl)ethyl]-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N12N=C(C=3C(=CC=CC=3)Cl)C(C=3C=CC(Cl)=CC=3)=C2N=C(C)N=C1NCCC1=CC=C(F)C=C1 QDDSPBSONLNBDS-UHFFFAOYSA-N 0.000 claims description 2
- UTVMMSUELWAQIR-UHFFFAOYSA-N 8-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)purin-6-yl]-1-propan-2-yl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound CC(C)N1CNC(=O)C11CCN(C=2C=3N=C(N(C=3N=CN=2)C=2C=CC(Cl)=CC=2)C=2C(=CC(Cl)=CC=2)Cl)CC1 UTVMMSUELWAQIR-UHFFFAOYSA-N 0.000 claims description 2
- HDPLEFUIDWOLLX-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-pyridin-2-ylpiperazin-1-yl)purine Chemical compound C1=CC(Cl)=CC=C1N1C2=NC=NC(N3CCN(CC3)C=3N=CC=CC=3)=C2N=C1C1=CC=C(Cl)C=C1Cl HDPLEFUIDWOLLX-UHFFFAOYSA-N 0.000 claims description 2
- VNOGOEOTNFURPS-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-pyrimidin-2-ylpiperazin-1-yl)purine Chemical compound C1=CC(Cl)=CC=C1N1C2=NC=NC(N3CCN(CC3)C=3N=CC=CN=3)=C2N=C1C1=CC=C(Cl)C=C1Cl VNOGOEOTNFURPS-UHFFFAOYSA-N 0.000 claims description 2
- PPNKCVSOPVJBPB-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(2-methylpropan-2-yl)oxy]purine Chemical compound N=1C=2C(OC(C)(C)C)=NC=NC=2N(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl PPNKCVSOPVJBPB-UHFFFAOYSA-N 0.000 claims description 2
- MOMMTIGOEFZQSC-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-propan-2-yloxypurine Chemical compound N=1C=2C(OC(C)C)=NC=NC=2N(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl MOMMTIGOEFZQSC-UHFFFAOYSA-N 0.000 claims description 2
- QMTNIILDNUELGY-UHFFFAOYSA-N 9-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-1-methyl-4-oxa-1,9-diazaspiro[5.5]undecan-2-one Chemical compound CN1C(=O)COCC11CCN(C=2C=3N=C(N(C=3N=CN=2)C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)CC1 QMTNIILDNUELGY-UHFFFAOYSA-N 0.000 claims description 2
- 239000005973 Carvone Substances 0.000 claims description 2
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 claims description 2
- UANAQVHSLHQZFG-UHFFFAOYSA-N n-[1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-oxoethyl]piperidin-4-yl]-2,2,2-trifluoroacetamide Chemical compound CC=1C(C(=O)CN2CCC(CC2)NC(=O)C(F)(F)F)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 UANAQVHSLHQZFG-UHFFFAOYSA-N 0.000 claims description 2
- MRKIECYDPOPRBO-UHFFFAOYSA-N n-butyl-7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1N2C(NCCCC)=NC(C)=NC2=C(C=2C=CC(Cl)=CC=2)C=1C1=CC=CC=C1Cl MRKIECYDPOPRBO-UHFFFAOYSA-N 0.000 claims description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims 1
- MJKOCBMDVCJJOQ-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-[4-(1-methylpyrrole-2-carbonyl)piperazin-1-yl]ethanone Chemical compound CC=1C(C(=O)CN2CCN(CC2)C(=O)C=2N(C=CC=2)C)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 MJKOCBMDVCJJOQ-UHFFFAOYSA-N 0.000 claims 1
- TWYJHYBZZKVEDR-UHFFFAOYSA-N 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-(methylamino)piperidine-4-carboxamide Chemical compound C1CC(NC)(C(N)=O)CCN1C1=NC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 TWYJHYBZZKVEDR-UHFFFAOYSA-N 0.000 claims 1
- OTRVURCEXHPIES-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-4-(4-methylphenyl)sulfonylmorpholine Chemical compound CC=1C(C2OCCN(C2)S(=O)(=O)C=2C=CC(C)=CC=2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 OTRVURCEXHPIES-UHFFFAOYSA-N 0.000 claims 1
- GXUYMCYBKGQKIC-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-4-cyclohexylmorpholine Chemical compound CC=1C(C2OCCN(C2)C2CCCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 GXUYMCYBKGQKIC-UHFFFAOYSA-N 0.000 claims 1
- OYJBJEBOPUMIRM-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-4-propan-2-ylsulfonylmorpholine Chemical compound C1N(S(=O)(=O)C(C)C)CCOC1C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1C OYJBJEBOPUMIRM-UHFFFAOYSA-N 0.000 claims 1
- NVEWRUMMUBKWLP-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(1-cyclohexylazetidin-3-yl)oxy-8-(2,4-dichlorophenyl)purine Chemical compound C1=CC(Cl)=CC=C1N1C2=NC=NC(OC3CN(C3)C3CCCCC3)=C2N=C1C1=CC=C(Cl)C=C1Cl NVEWRUMMUBKWLP-UHFFFAOYSA-N 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 125000006178 methyl benzyl group Chemical group 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000003556 assay Methods 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 239000000556 agonist Substances 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- YNZFFALZMRAPHQ-SYYKKAFVSA-N 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]1[C@H](CCCO)CC[C@@H](O)C1 YNZFFALZMRAPHQ-SYYKKAFVSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 102000003840 Opioid Receptors Human genes 0.000 description 8
- 108090000137 Opioid Receptors Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 102000051367 mu Opioid Receptors Human genes 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 108020001612 μ-opioid receptors Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229930003827 cannabinoid Natural products 0.000 description 6
- 239000003557 cannabinoid Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 5
- 206010001584 alcohol abuse Diseases 0.000 description 5
- 208000025746 alcohol use disease Diseases 0.000 description 5
- 108700023159 delta Opioid Receptors Proteins 0.000 description 5
- 102000048124 delta Opioid Receptors Human genes 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 4
- 108050007331 Cannabinoid receptor Proteins 0.000 description 4
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 4
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229950007919 egtazic acid Drugs 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108020001588 κ-opioid receptors Proteins 0.000 description 4
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- BUZAJRPLUGXRAB-UHFFFAOYSA-N AM-251 Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(I)C=C1 BUZAJRPLUGXRAB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229940124802 CB1 antagonist Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- JUXWUYWPUDKPSD-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine Chemical class N1=CN=CN2N=CC=C21 JUXWUYWPUDKPSD-UHFFFAOYSA-N 0.000 description 2
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 201000006152 substance dependence Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- ICQCQBMJTILLBT-UHFFFAOYSA-N 1-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-3-(ethylamino)azetidine-3-carboxamide Chemical compound C1C(NCC)(C(N)=O)CN1C1=CC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 ICQCQBMJTILLBT-UHFFFAOYSA-N 0.000 description 1
- VZRIQXJDFHMUGK-UHFFFAOYSA-N 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)purin-6-yl]-4-(methylamino)piperidine-4-carboxamide Chemical compound C1CC(NC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC(Cl)=CC=1)Cl)N2C1=CC=C(Cl)C=C1 VZRIQXJDFHMUGK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- REOYOKXLUFHOBV-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidin-1-ylpyrazole-3-carboxamide;hydron;chloride Chemical compound Cl.CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 REOYOKXLUFHOBV-UHFFFAOYSA-N 0.000 description 1
- CYAYCOCJAVHQSD-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CYAYCOCJAVHQSD-UHFFFAOYSA-N 0.000 description 1
- GTEQPYBNPXBWBT-UHFFFAOYSA-N 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-methylpiperazin-1-yl)pyrazolo[1,5-a][1,3,5]triazine Chemical compound C1CN(C)CCN1C1=NC(C)=NC2=C(C=3C=CC(Cl)=CC=3)C(C=3C(=CC=CC=3)Cl)=NN12 GTEQPYBNPXBWBT-UHFFFAOYSA-N 0.000 description 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012488 Opiate Overdose Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VVBXXVAFSPEIJQ-CVIPOMFBSA-N [(2r)-3-[[(2r)-1-[[(2s,5r,8r,11r,12s,15s,18s,21s)-15-[3-(diaminomethylideneamino)propyl]-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]am Chemical compound C([C@@H]1C(=O)N[C@@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H]2CC[C@H](O)N(C2=O)[C@@H](CC(C)C)C(=O)N1C)=O)NC(=O)[C@H](NC(=O)[C@H](O)COS(O)(=O)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 VVBXXVAFSPEIJQ-CVIPOMFBSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000002472 amphetamine abuse Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001962 neuropharmacologic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49680303P | 2003-08-21 | 2003-08-21 | |
| PCT/IB2004/002596 WO2005018645A1 (en) | 2003-08-21 | 2004-08-09 | A pharmaceutical composition for the prevention and treatment of addiction in a mammal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502808A true JP2007502808A (ja) | 2007-02-15 |
| JP2007502808A5 JP2007502808A5 (https=) | 2007-08-16 |
Family
ID=34216038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523697A Pending JP2007502808A (ja) | 2003-08-21 | 2004-08-09 | 哺乳類における依存症の予防と治療のための薬剤組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050043327A1 (https=) |
| EP (1) | EP1658082A1 (https=) |
| JP (1) | JP2007502808A (https=) |
| BR (1) | BRPI0413693A (https=) |
| CA (1) | CA2536280A1 (https=) |
| MX (1) | MXPA06002035A (https=) |
| WO (1) | WO2005018645A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010013591A1 (ja) | 2008-07-30 | 2010-02-04 | Hirai Koji | 擬似嗜好物品 |
| JP2012512873A (ja) * | 2008-12-18 | 2012-06-07 | イーライ リリー アンド カンパニー | プリン化合物 |
| WO2018159716A1 (ja) * | 2017-03-02 | 2018-09-07 | 株式会社 三和化学研究所 | アルコール使用障害の治療薬 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1440059B1 (en) * | 2001-10-22 | 2008-04-16 | Pfizer Products Inc. | 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists |
| CA2499994C (en) * | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| US7132426B2 (en) * | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| AU2006305104B2 (en) * | 2005-10-21 | 2009-10-22 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| JP5269795B2 (ja) * | 2006-09-29 | 2013-08-21 | グリーン・クロス・コーポレイション | カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体 |
| WO2008044111A1 (en) * | 2006-10-13 | 2008-04-17 | Pfizer Products Inc. | Pharmaceutical formulation tablet |
| US8252791B2 (en) * | 2008-08-13 | 2012-08-28 | Jenrin Discovery, Inc. | Purine compounds as cannabinoid receptor blockers |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| JP2013542243A (ja) | 2010-11-15 | 2013-11-21 | カトリーケ ウニヴェルシテイト ルーヴェン | 新規な抗ウイルス性化合物 |
| US9663463B2 (en) | 2013-11-20 | 2017-05-30 | Sanwa Kagaku Kenkyusho Co., Ltd. | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| KR20180004734A (ko) | 2015-05-20 | 2018-01-12 | 가부시키가이샤산와카가쿠켄큐쇼 | 신규 3-아자비시클로［3.1.0］헥산 유도체의 염의 결정 및 그의 의약 용도 |
| CA3036382A1 (en) * | 2016-12-21 | 2018-06-28 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
| SG11202007422QA (en) * | 2018-02-05 | 2020-09-29 | Alkermes Inc | Compounds for the treatment of pain |
| WO2023064228A1 (en) * | 2021-10-11 | 2023-04-20 | Anebulo Pharmaceuticals, Inc. | Method of treating addiction |
| AU2022362107A1 (en) | 2021-10-11 | 2024-05-02 | Anebulo Pharmaceuticals, Inc. | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035622A1 (en) * | 2001-10-22 | 2003-05-01 | Pfizer Products Inc. | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003267728A1 (en) * | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
-
2004
- 2004-06-17 US US10/870,209 patent/US20050043327A1/en not_active Abandoned
- 2004-08-09 JP JP2006523697A patent/JP2007502808A/ja active Pending
- 2004-08-09 CA CA002536280A patent/CA2536280A1/en not_active Abandoned
- 2004-08-09 BR BRPI0413693-4A patent/BRPI0413693A/pt not_active IP Right Cessation
- 2004-08-09 WO PCT/IB2004/002596 patent/WO2005018645A1/en not_active Ceased
- 2004-08-09 MX MXPA06002035A patent/MXPA06002035A/es not_active Application Discontinuation
- 2004-08-09 EP EP04744231A patent/EP1658082A1/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035622A1 (en) * | 2001-10-22 | 2003-05-01 | Pfizer Products Inc. | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010013591A1 (ja) | 2008-07-30 | 2010-02-04 | Hirai Koji | 擬似嗜好物品 |
| JP2012512873A (ja) * | 2008-12-18 | 2012-06-07 | イーライ リリー アンド カンパニー | プリン化合物 |
| WO2018159716A1 (ja) * | 2017-03-02 | 2018-09-07 | 株式会社 三和化学研究所 | アルコール使用障害の治療薬 |
| JPWO2018159716A1 (ja) * | 2017-03-02 | 2019-12-26 | 株式会社三和化学研究所 | アルコール使用障害の治療薬 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2536280A1 (en) | 2005-03-03 |
| BRPI0413693A (pt) | 2006-10-24 |
| WO2005018645A1 (en) | 2005-03-03 |
| EP1658082A1 (en) | 2006-05-24 |
| US20050043327A1 (en) | 2005-02-24 |
| MXPA06002035A (es) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502808A (ja) | 哺乳類における依存症の予防と治療のための薬剤組成物 | |
| JP6604664B2 (ja) | 核内受容体に対して活性な化合物 | |
| ES2205574T3 (es) | Derivados de 2-aril-8-oxohidropurina, procedimiento de produccion de estos derivados, composiciones medicinales que contienen estos derivados, e intermediarios de estos derivados. | |
| CN105492439B (zh) | 作为溴结构域抑制剂的取代的双环化合物 | |
| AU2003304527B2 (en) | Uses of adenosine A2a receptor antagonists | |
| EP2931280B1 (en) | Methods and compositions for inhibiting cnksr1 | |
| OA12554A (en) | Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. | |
| Megens et al. | Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs | |
| CA2942821A1 (en) | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome | |
| JP2002536291A (ja) | ２−（４−アリール又はヘテロアリール−ピペラジン−１−イルメチル）−１ｈ−インドール誘導体 | |
| KR20090121358A (ko) | 5-ｈｔ2ｃ 작용제로서 피리미도 [4,5-ｄ] 아제핀 유도체 | |
| WO2024168098A2 (en) | 5-methoxy-n,n-dimethyltryptamine analogs, their synthesis, and methods for treatment of neurological, psychiatric, and substance use disorders | |
| RU2384581C2 (ru) | ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| CA2772922C (en) | Thiazoles derivatives for treating or preventing anxiety disorders | |
| JP2008150371A (ja) | 性機能障害を治療するための化合物 | |
| JP2006525992A (ja) | 哺乳動物におけるニコチン嗜癖の予防及び治療のための医薬組成物 | |
| MXPA04012389A (es) | Composiciones anti-inflamatorias y metodos de uso. | |
| JP2009511588A (ja) | 錐体外路症候群および他の運動障害の処置のためのアデノシンＡ２ａレセプターアンタゴニスト | |
| RU2500672C1 (ru) | (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения | |
| US20040224962A1 (en) | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | |
| JP2006528171A (ja) | 男性機能障害の治療 | |
| JP2010515690A (ja) | 医薬品の多形及び溶媒和物、並びに製造方法 | |
| RU2815636C1 (ru) | Необязательно конденсированные гетероциклил-замещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний | |
| Megens et al. | Pharmacology of JNJ42314415, a centrally active PDE10A inhibitor. A comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotics | |
| CN121108035A (zh) | 具有Sigma-1/H3受体双靶点活性的化合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070629 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100629 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101130 |